在印度观察到目标公司的不合规行为并不一定会阻碍交易过程。然而，全面的尽职调查需要进行影响评估并采取量身定制的补救策略，以降低风险敞口并确保顺利的交易。通过采取商业务实的方式，外国投资者可以有效应对印度的合规环境并实现成功的交易完成。

在过去的十年间，印度已从跨国公司医疗器械市场和研究中心发展成为一个重要的制造中心。该行业的市值为120亿美元，其增长得益于政府的战略举措、监管改革、熟练的工程人才以及精密制造能力。 印度医疗器械行业概览 2023-2024财年，印度的医疗器械行业 ...

India's Union Budget 2025-26 introduces several revisions to taxation policies, besides provisions for focus industries and ...

The Economic Survey of India 2024-25 offers an optimistic outlook for India's economic growth, emphasizing resilience, ...

India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.

India's defense manufacturing sector is poised for growth with the government's push for domestic production, FDI relaxations ...

The DGFT has launched the enhanced eCoO 2.0 system to streamline export certification processes in India and boost trade ...

Singapore President Tharman’s first visit to India highlights strong bilateral ties and active collaboration in emerging ...

India’s CBDT has said that investments from Mauritius, Cyprus, and Singapore before April 1, 2017, retain favorable capital ...

India and China agree to resume direct flights, visa issuance, and the Kailash Mansarovar Yatra for pilgrims, following renewed diplomatic engagement.